Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study


Departments of Obstetrics and Gynaecology, Internal Medicine and Clinical Chemistry, University Hospital of Oulu, PO Box 24, 90029 Oulu, Finland

Abstract

Objective: Abdominal obesity, insulin resistance and compensatory hyperinsulinaemia play a central role in the pathogenesis of the polycystic ovary syndrome (PCOS). Abdominal adipose tissue is a source of adipokines, such as adiponectin and resistin, both of which may be involved in the development of insulin resistance and chronic inflammation in PCOS. Ghrelin, an important regulatory peptide of food intake, may also play a role in metabolic disturbances related to PCOS.

The aim of this study was to examine the effects of 4 months of treatment with the insulin sensitizer rosiglitazone on plasma adiponectin, resistin and ghrelin levels in overweight women with PCOS.

Design: A randomised placebo-controlled study.

Methods: Thirty overweight/obese women with PCOS (body mass index > 25 kg/m², mean age 29.1 ± 1.2 (S.E.M.) years) were randomly allocated to either rosiglitazone (Avandia, 4 mg twice a day) or placebo treatment. Plasma levels of adiponectin, resistin and ghrelin and their correlation to serum levels of insulin, C-peptide and steroid hormones, and insulin sensitivity (euglycaemic hyperinsulinaemic clamp) were assessed.

Results: Adiponectin and ghrelin levels correlated significantly with most metabolic markers of insulin resistance and with serum levels of DHEA and 17-hydroxyprogesterone. Plasma levels of adiponectin increased from 9.26 ± 0.90 (S.E.M.) to 22.22 ± 3.66 mg/ml (P < 0.001) and those of resistin decreased from 12.57 ± 1.63 to 9.21 ± 0.53 ng/ml (P = 0.009) at 4 months of treatment, but plasma ghrelin levels did not change.

Conclusions: Rosiglitazone had beneficial effects on serum levels of adiponectin and resistin, suggesting that these adipocytokines may contribute to the improvement in insulin sensitivity observed during the treatment.

Introduction

Abdominal obesity, insulin resistance and compensatory hyperinsulinaemia play a central role in the pathogenesis of polycystic ovary syndrome (PCOS), the most common endocrine disorder and cause of anovulatory infertility in women (1, 2). Abdominal adiposity per se is a specific and independent risk factor as regards insulin resistance, cardiovascular disease (3–5), glucose intolerance and type 2 diabetes mellitus (6, 7). Moreover, adipose tissue is a source of free fatty acids (FFAs) and adipokines, such as adiponectin and resistin (5).

Adiponectin is particularly expressed in adipose tissue (8), and it may have a role in preventing the development of insulin resistance (9, 10). The production of adiponectin is decreased in obesity (8, 9), and its plasma levels have been shown to correlate negatively with waist-to-hip ratio (WHR, 11) and body mass index (BMI, 8). Decreased plasma levels of adiponectin have been observed in subjects with type 2 diabetes mellitus and coronary artery disease (12), and in women with PCOS (13–16).

The insulin sensitizer rosiglitazone, one of the thiazolidinediones (TZDs), activates peroxisome proliferator-activated receptor-γ (PPARγ), an adipocyte transcription factor. This stimulates adipocyte differentiation to adipocytes in which adiponectin is secreted (17–20). Adiponectin improves glucose transport into cells and insulin sensitivity (21). The TZDs also inhibit inflammatory cytokine production and thereby the development of atherosclerosis (22). The beneficial effect of rosiglitazone on adiponectin secretion and insulin sensitivity has been demonstrated in subjects with type 2 diabetes mellitus and with impaired glucose tolerance (23, 24).

Another adipokine, resistin, is expressed in macrophages and to a lesser extent in mature adipocytes in
humans (25). The results of some studies have suggested that elevated resistin levels may be associated with insulin resistance in diabetic subjects (26, 27) and with chronic inflammation, independent of obesity (28), and could be predictive as regards the development of cardiovascular disease (29). Increased plasma resistin concentrations have also been found in women with PCOS compared with women without the syndrome in some (14, 30), but not in all studies (31–33). Rosiglitazone treatment has been shown to decrease resistin plasma levels among HIV-infected subjects with insulin resistance (34) and in patients with diabetes mellitus (35), and has been suggested to have a direct reducing effect on resistin through macrophage PPARγ activation in humans (36, 37).

Ghrelin, a peptide produced primarily by the endocrine cells in the stomach (38), is an endogenous ligand of the growth hormone (GH) secretagogue receptor and stimulates GH secretion (39). It has been suggested to be an important regulatory peptide in food intake, long-term body weight regulation, glucose metabolism and ovarian function (39, 40). Low serum ghrelin levels have been shown to be associated with abdominal obesity, hyperinsulinaemia and insulin resistance in type 2 diabetic patients (41, 42) and to be decreased in women with PCOS (43).

The aim of the present study was to investigate the effects of rosiglitazone on adiponectin and resistin as well as on ghrelin levels in PCOS subjects, and to assess the correlations of adiponectin, resistin and ghrelin concentrations with various anthropometric and metabolic variables.

Materials and methods

Subjects

The subjects included in this study have participated in our earlier studies on the effects of rosiglitazone on insulin sensitivity, glucose tolerance and hormonal parameters (44), and on low-grade inflammation and liver function in PCOS (45). Thirty women with PCOS (BMI > 5 kg/m², mean age 29.1 ± 1.2 (S.E.M.) years, range 18–41) were recruited from the Reproductive Endocrine Unit at Oulu University Hospital (44). The criteria for PCOS were defined according to the new consensus criteria (46). Diabetic subjects, subjects who had signs of liver or renal failure or active liver disease (ALT > 2.5 × the upper limit of normal values), smokers, alcohol users and those taking medication known to affect reproductive or metabolic functions within 2 months of the study were excluded. One subject from each group discontinued the study for personal reasons and two became pregnant in the rosiglitazone group. In the rosiglitazone group, 12 women completed the study and 14 in the placebo group.

The study was approved by the Ethics Committee of Oulu University Hospital, and informed written consent was obtained from each subject.

Protocol of the study

The subjects were randomly and blindly allocated to receive either rosiglitazone (ROSI group: Avandia, GlaxoSmithKline, PA, 4 mg once daily for 2 weeks, then 4 mg twice daily) or placebo (PLA group) for 4 months, as published previously (44). All subjects were examined 1–7 days after spontaneous or progestin-induced (oligomenorrhoeic and amenorrhoeic subjects) menstruation before treatment and at 4 months of treatment. They received instructions regarding a weight-maintenance diet throughout the study. The weight of the subjects, fasting glucose, haemoglobin, haematocrit, liver enzymes and urinary pregnancy test results were assessed monthly during the study.

Waist and hip circumferences were measured to the nearest centimetre with a soft tape at the narrowest part of the torso and at the widest part of the gluteal region. Transvaginal ultrasonography, the oral glucose tolerance test (OGTT), the i.v. glucose tolerance test (IVGTT), the euglycaemic hyperinsulinaemic clamp (to determine the level of insulin sensitivity, i.e. whole-body glucose disposal rate, M value) and calorimetry to assess glucose and fat oxidation rates were carried out and blood samples for glucose levels, serum concentrations of insulin, C-peptide, sex hormone-binding globulin (SHBG), C-reactive protein (CRP) and steroid hormones were drawn as described previously (44). The incremental insulin (AUCins) and glucose (AUCgluc) areas under the curve during the OGTT were calculated by the trapezoidal method. The free androgen index (FAI) was calculated according to the equation: (testosterone (T) × 100)/SHBG, with T and SHBG expressed in nanomoles per litre.

Assays and calculations

The samples for blood glucose levels, serum concentrations of insulin, C-peptide, SHBG, CRP and steroid hormones were analysed as previously described (44).

Plasma adiponectin concentrations were measured in triplicate by means of an ELISA devised in our laboratory: monoclonal anti-human adiponectin antibody at 2 μg/ml (R&D-systems, Cat. MAB10651) was used as a capture antibody and biotinylated monoclonal anti-human adiponectin antibody at 1.5 μg/ml (R&D-systems, Cat. MAB1065) was used as a detection antibody. For detection of biotin-labelled antibody, we used 1:18 000 diluted alkaline phosphatase-labelled NeutrAvidin (Pierce Cat. 31 002) and 30% Lumiphos 530 (Lumigen, Cat. P-501). A standard curve from 1.56 to 60 ng/ml was prepared from human recombinant adiponectin (Biovendor, Cat.
Plasma samples were diluted at a ratio of 1:1000 and the concentrations were measured in duplicate. The intra-assay coefficient of variation of the method was 11.1% and the inter-assay variation was 4.5%. Baseline and post-treatment samples from individual subjects were measured in the same assay.

Plasma resistin levels were measured in duplicate using a commercially available enzyme-linked immunoassay kit (Linco Research Inc., MO, USA; intra- and inter-assay coefficients of variation being 4.5 and 7.4% respectively) according to the manufacturer’s instructions. Baseline and post-treatment samples from individual subjects were measured in the same assay.

Plasma total ghrelin concentrations were measured in duplicate using a commercial RIA (Linco Research, Inc., USA; intra-assay coefficient of variation 2.65%). Measurement was carried out according to the manufacturer’s instructions.

**Statistical methods**

The paired t-test was used to compare the changes of clinical, metabolic and hormonal parameters within the ROSI and PLA groups during the treatment. Wilcoxon’s unpaired test was used for variables with persisting skewed distribution after log transformation. For comparison of the ROSI and PLA groups before the treatment, Student’s two-tailed t-test was used for normally distributed variables. The Mann–Whitney U-test was used for variables with persisting skewed distribution after log transformation. The comparison of changes after treatment between rosiglitazone and placebo groups was assessed by ANOVA for repeated measures.

Analysis of correlation between parameters was performed by calculating Pearson’s bivariate correlation coefficient.

**Results**

**Baseline characteristics**

All the subjects of the study had polycystic ovaries at echography. In the ROSI group, seven subjects displayed both oligo-/amenorrhea and hirsutism, two had oligomenorrhea only and three hirsutism only. In the PLA group, all the subjects were hirsute and ten displayed also oligo-/amenorrhea.

At baseline, the ROSI and PLA groups did not differ with respect to age (30.1 ± 2.1 in the ROSI group vs 27.1 ± 1.1 years in the PLA group), BMI (33.7 ± 1.0 in the ROSI group vs 33.6 ± 1.0 kg/m² in the PLA group), WHR (0.87 ± 0.01 in the ROSI group vs 0.87 ± 0.01 in the PLA group), hirsutism score (9.8 ± 1.5 in the ROSI group vs 8.8 ± 0.9 in the PLA group) and menstrual cycle. The baseline hormonal and metabolic parameters have been published earlier (44).

Adiponectin and resistin levels were similar in the ROSI and PLA groups at baseline (Fig. 1). The significant correlations of adiponectin, resistin and ghrelin with anthropometric and metabolic variables are presented in Table 1. Adiponectin and ghrelin concentrations correlated significantly with most metabolic markers of insulin resistance and with the levels of some androgens such as DHEA and 17-OHP, but no significant correlation was found with lipid levels or inflammatory parameters (Table 1).

**Changes during rosiglitazone treatment**

Plasma levels of adiponectin increased (from $9.26 \pm 0.90$ (S.E.M.) to $22.22 \pm 3.66$ μg/ml, $P<0.001$) and plasma resistin levels decreased (from $12.57 \pm 1.63$ to $9.21 \pm 0.53$ ng/ml, $P=0.009$) significantly during the 4 months of treatment with rosiglitazone. During the 4 months’ treatment with rosiglitazone, the changes in serum levels of adiponectin ($P<0.001$) and resistin ($P=0.03$) were significant compared with the changes
A Majuri and others

Glucose non-oxidation

P Clamp FFA

P DHEAS

P FAI

P DHEA

P 17-OHP

P Androstenedione

P Clamp FFA

P Glucose non-oxidation

Table 1 Significant correlations between adiponectin, resistin and ghrelin with anthropometric metabolic and hormonal parameters at baseline in the whole study group.

<table>
<thead>
<tr>
<th>No. of subjects</th>
<th>Adiponectin</th>
<th>Resistin</th>
<th>Ghrelin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N = 30</td>
<td>N = 30</td>
<td>N = 30</td>
</tr>
<tr>
<td>BMI</td>
<td>P = 0.008</td>
<td>P = 0.700</td>
<td>P = 0.298</td>
</tr>
<tr>
<td></td>
<td>r = -0.521</td>
<td>r = 0.081</td>
<td>r = 0.221</td>
</tr>
<tr>
<td>Waist</td>
<td>P = 0.228</td>
<td>P = 0.835</td>
<td>P = 0.050</td>
</tr>
<tr>
<td></td>
<td>r = 0.250</td>
<td>r = 0.044</td>
<td>r = 0.397</td>
</tr>
<tr>
<td>Hip</td>
<td>P = 0.028</td>
<td>P = 0.941</td>
<td>P = 0.820</td>
</tr>
<tr>
<td></td>
<td>r = -0.440</td>
<td>r = 0.016</td>
<td>r = 0.048</td>
</tr>
<tr>
<td>WHR</td>
<td>P = 0.932</td>
<td>P = 0.867</td>
<td>P = 0.026</td>
</tr>
<tr>
<td></td>
<td>r = -0.018</td>
<td>r = -0.035</td>
<td>r = 0.444</td>
</tr>
<tr>
<td>Fasting insulin</td>
<td>P = 0.002</td>
<td>P = 0.208</td>
<td>P = 0.055</td>
</tr>
<tr>
<td></td>
<td>r = -0.587</td>
<td>r = 0.261</td>
<td>r = 0.388</td>
</tr>
<tr>
<td>AUC-insulin</td>
<td>P = 0.353</td>
<td>P = 0.781</td>
<td>P = 0.001</td>
</tr>
<tr>
<td></td>
<td>r = -0.203</td>
<td>r = 0.061</td>
<td>r = 0.681</td>
</tr>
<tr>
<td>C peptide</td>
<td>P = 0.006</td>
<td>P = 0.049</td>
<td>P = 0.264</td>
</tr>
<tr>
<td></td>
<td>r = -0.535</td>
<td>r = 0.397</td>
<td>r = 0.232</td>
</tr>
<tr>
<td>M value</td>
<td>P = 0.031</td>
<td>P = 0.234</td>
<td>P = 0.023</td>
</tr>
<tr>
<td></td>
<td>r = -0.433</td>
<td>r = 0.247</td>
<td>r = 0.453</td>
</tr>
<tr>
<td>AUC-glucose</td>
<td>P = 0.208</td>
<td>P = 0.392</td>
<td>P = 0.029</td>
</tr>
<tr>
<td></td>
<td>r = -0.266</td>
<td>r = 0.183</td>
<td>r = 0.447</td>
</tr>
<tr>
<td>FAI</td>
<td>P = 0.194</td>
<td>P = 0.079</td>
<td>P = 0.014</td>
</tr>
<tr>
<td></td>
<td>r = 0.269</td>
<td>r = 0.358</td>
<td>r = 0.487</td>
</tr>
<tr>
<td>DHEA</td>
<td>P = 0.025</td>
<td>P = 0.315</td>
<td>P = 0.115</td>
</tr>
<tr>
<td></td>
<td>r = 0.448</td>
<td>r = 0.209</td>
<td>r = 0.232</td>
</tr>
<tr>
<td>DHEAS</td>
<td>P = 0.077</td>
<td>P = 0.205</td>
<td>P = 0.023</td>
</tr>
<tr>
<td></td>
<td>r = 0.360</td>
<td>r = 0.263</td>
<td>r = 0.453</td>
</tr>
<tr>
<td>17-OHP</td>
<td>P = 0.036</td>
<td>P = 0.695</td>
<td>P = 0.418</td>
</tr>
<tr>
<td></td>
<td>r = -0.422</td>
<td>r = 0.083</td>
<td>r = 0.169</td>
</tr>
<tr>
<td>Androstenedione</td>
<td>P = 0.141</td>
<td>P = 0.404</td>
<td>P = 0.051</td>
</tr>
<tr>
<td></td>
<td>r = 0.303</td>
<td>r = 0.174</td>
<td>r = 0.395</td>
</tr>
<tr>
<td>Clamp FFA</td>
<td>P = 0.039</td>
<td>P = 0.013</td>
<td>P = 0.152</td>
</tr>
<tr>
<td></td>
<td>r = -0.416</td>
<td>r = 0.492</td>
<td>r = 0.295</td>
</tr>
<tr>
<td>Glucose non-oxidation</td>
<td>P = 0.004</td>
<td>P = 0.179</td>
<td>P = 0.049</td>
</tr>
<tr>
<td></td>
<td>r = 0.560</td>
<td>r = 0.278</td>
<td>r = 0.398</td>
</tr>
</tbody>
</table>

during placebo treatment. Treatment with placebo did not affect adiponectin and resistin levels (Fig. 1).

The increase in adiponectin levels during the treatment correlated significantly with the decrease in the serum FFA levels during the euglycaemic clamp (P = 0.017; r = -0.76, Table 2 and Fig. 2). The other correlations between the changes in adiponectin and resistin levels and those in metabolic and endocrine variables during the rosiglitazone treatment did not reach statistical significance (Table 2).

Plasma ghrelin levels did not change significantly during rosiglitazone (744.2 ± 106.6 vs 780.9 ± 52.1 pg/ml) or placebo treatment (969.6 ± 124.1 vs 1287.0 ± 197.7 pg/ml).

Discussion

The present results demonstrated that treatment with rosiglitazone had a significant effect on plasma adipokine levels, increasing plasma adiponectin and decreasing resistin levels in overweight women with PCOS. In contrast, no change was observed in the plasma ghrelin levels.

At baseline, plasma levels of adiponectin correlated negatively with BMI, serum insulin and C-peptide levels, and positively with the whole body glucose disposal rate (M value) and non-oxidative glucose disposal, but not with oxidative glucose disposal before or during the clamp. These findings are in line with the results of earlier studies (47–49) suggesting that adiponectin is strongly associated with insulin sensitivity in humans. More
specifically, adiponectin could control insulin sensitivity mainly by modulating non-oxidative glucose disposal, i.e. the glycogen synthesis pathway in human skeletal muscle (50). It is interesting to note that plasma adiponectin levels correlated significantly with FFA levels at baseline, and during rosiglitazone treatment, the changes of adiponectin and clamp FFA concentrations were significantly and negatively associated. These findings suggest an active role of adiponectin not only in the improvement of insulin sensitivity during rosiglitazone treatment, but also in the regulation of fat tissue metabolism.

Treatment with rosiglitazone increased plasma adiponectin levels more than twofold in PCOS subjects. Similar changes in adiponectin levels during rosiglitazone treatment have been observed in patients with impaired glucose tolerance (23), type 2 diabetes (24), 50 and in one non-placebo-controlled study in women with PCOS (13). In a previous study, we demonstrated that the well-known risk factors for coronary heart disease and type 2 diabetes, serum levels of CRP and white blood cell count (51–55), decreased during rosiglitazone treatment (Rautio et al. in press). Thus, the present findings further support a beneficial effect of rosiglitazone on metabolic and cardiovascular risk factors in PCOS.

Rosiglitazone treatment significantly decreased plasma resistin levels in overweight women with PCOS. A similar effect of rosiglitazone has been reported in type 2 diabetic patients (35) and in HIV-positive subjects with insulin resistance (34). The role of resistin in humans is not well understood. It has been found to be correlated with insulin resistance (26) and to have proinflammatory regulatory properties in human monocytes in vitro (56) and in diabetic patients (28). Furthermore, elevated levels of resistin have been associated with coronary atherosclerosis (29). The present data suggest that rosiglitazone, by decreasing plasma resistin levels, may have beneficial effects in the prevention of atherosclerosis and cardiovascular diseases in women with PCOS.

Plasma ghrelin concentrations did not change during rosiglitazone treatment, which could be a result of the relatively low number of subjects in the rosiglitazone group and the large variation of ghrelin levels between subjects. However, in line with the results of previous studies (42, 57–59), the baseline plasma levels of ghrelin were significantly associated with the key parameters related to abdominal obesity and insulin resistance, such as WHR, AUC\textsubscript{ins}, AUC\textsubscript{gluc} and M value, the best indicator of insulin sensitivity (60). Plasma levels of ghrelin correlated negatively with androgen levels and the FAI, suggesting that ghrelin may also be related to hyperandrogenism in PCOS.

In conclusion, rosiglitazone treatment increased plasma levels of adiponectin and decreased plasma levels of resistin in overweight women with PCOS, suggesting that these adipocytokines may contribute to the improvement in insulin sensitivity observed during rosiglitazone treatment.

Acknowledgements

Grants: This work was supported by grants from the Academy of Finland, the Sigrid Jusélius Foundation and Oulu University Hospital.

References

16 Ardawi MS & Rouzi AA. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertility and Sterility 2005 83 1708–1716.


www.eje-online.org


Received 1 September 2006
Accepted 8 November 2006